Search Results

Unprotected Left Main Coronary Intervention

In patients with significant obstructive left main coronary artery disease, initial studies showed that coronary artery bypass graft surgery (CABG) improved long-term survival compared with medical therapy.1-3 Since publication of these studies, CABG has been considered the standard of care for revascularization of left main coronary artery disease in the absence of previous bypass grafts to branches of the left coronary artery—so-called unprotected left main (ULM) revascularization.

AHA Issues Statement on Arteriotomy Closure Devices for Cardiovascular Procedures

November 2, 2010—The American Heart Association (AHA) has issued a scientific statement on arteriotomy closure devices (ACDs) for cardiovascular procedures.

Updated Appropriate Use Criteria Address Coronary Revascularization for Patients With Stable Ischemic Heart Disease

March 13, 2017—The American College of Cardiology (ACC) announced the release of multisociety updated appropriate use criteria for performing coronary revascularization in patients with stable ischemic heart disease.

Multisociety Appropriate-Use Criteria Address Coronary Revascularization for ACS

December 22, 2016–The American College of Cardiology (ACC) announced the publication of an updated, multisociety appropriate use criteria (AUC) for performing coronary revascularization in patients with acute coronary syndromes (ACS).

Appropriate Use of PCI Studied

July 5, 2011—Paul S. Chan, MD, et al published a study in the Journal of the American Medical Association to quantify the proportion of percutaneous coronary interventions (PCIs) classified as appropriate, of uncertain appropriateness, and inappropriate for acute as well as nonacute indications (2011;306:53–61). The investigators concluded that approximately all PCIs for acute indications could be classified as appropriate, whereas only approximately half of PCIs performed for nonacute indications could be classified as appropriate.

Abiomed's MINI-AMI Study Commenced and CRISP-AMI Results Published

September 19, 2011—Abiomed, Inc. (Danvers, MA) announced that the first patient was enrolled in the MINI-AMI (Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction) trial.